RMD ResMedcompanySEC Filings & Insider Trading Activity 2026
Latest ResMed (RMD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on August 8, 2025, a 10-Q quarterly report filed on January 30, 2026, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ResMed (RMD) (SEC CIK 943819), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-06-30)
Risk Factors
- • Delaware corporate law provisions enable issuance of 2.0 million preferred shares without stockholder approval
- • Charter anti-takeover provisions potentially delaying beneficial management changes or acquisition offers
Management Discussion & Analysis
- • Revenue split into Sleep and Breathing Health and Residential Care Software segments; revenue recognized on shipment and service provision respectively
- • Rebates, discounts, and credits reduce Sleep and Breathing Health revenue, estimated via historical data and sales targets quarterly or annually
Business Overview
- • Core business model: Design, manufacture, and distribute medical devices for respiratory care and sleep apnea management
- • Emphasis on enhanced cybersecurity governance with CISO-led program and annual board updates on risk landscape and incident response
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-12-31)
Management Discussion & Analysis
- • Revenue $1.423B for Q2 FY2025, up 11% YoY from $1.282B in Q2 FY2024; Sleep and Breathing Health segment up 12%, Residential Care Software up 7%
- • Gross margin 61.8% in Q2 FY2025 vs 58.6% YoY; operating expenses increased, SG&A 19.6% of revenue vs 18.8% YoY, R&D at 6.4% vs 6.3%
Risk Factors
- • No new or changed risk factors since 10-K for fiscal year ended June 30, 2025
- • Continued exposure to product liability risks from medical device use as previously disclosed
Annual Reports Archive10-K
AI-powered analysis of ResMed (RMD) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ResMed (RMD) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B |
| Gross Profit | $2.0B | $2.4B | $2.7B | $3.1B |
| Operating Income | — | $1.1B | $1.3B | $1.7B |
| Net Income | — | $897.6M | $1.0B | $1.4B |
| Gross Margin | 56.6% | 55.8% | 56.7% | 59.4% |
| Op. Margin | — | 26.8% | 28.2% | 32.7% |
| Net Margin | — | 21.3% | 21.8% | 27.2% |
| Balance Sheet | ||||
| Total Assets | — | $6.8B | $6.9B | $8.2B |
| Equity | — | $4.1B | $4.9B | $6.0B |
| ROE | — | 21.7% | 21.0% | 23.5% |
Source: XBRL financial data from ResMed (RMD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Apr 30, 2026 | — | — | — |
10-Q | Jan 30, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 29, 2026 | — | — | |
10-Q | Oct 31, 2025 | Sep 30, 2025 | Analysis | |
10-K | Aug 8, 2025 | Jun 30, 2025 | Analysis | |
10-Q | Apr 24, 2025 | Mar 31, 2025 | Analysis | |
10-Q | Jan 31, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 25, 2024 | Sep 30, 2024 | — | |
10-K | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 26, 2024 | Mar 31, 2024 | — | |
10-Q | Jan 25, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 27, 2023 | Sep 30, 2023 | — | |
10-K | Aug 11, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 28, 2023 | Mar 31, 2023 | — | |
10-Q | Jan 27, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 28, 2022 | Sep 30, 2022 | — | |
10-K | Aug 12, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 29, 2022 | Mar 31, 2022 | — | |
10-Q | Jan 28, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 29, 2021 | Sep 30, 2021 | — | |
10-K | Aug 17, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 30, 2021 | Mar 31, 2021 | — | |
10-Q | Jan 29, 2021 | Dec 31, 2020 | — | |
10-Q | Oct 30, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest RMD SEC filings in 2026?
ResMed (RMD) has filed a 10-K annual report on August 8, 2025, a 10-Q quarterly report on January 30, 2026, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did RMD file its most recent 10-K annual report?
ResMed (RMD) filed its most recent 10-K annual report on August 8, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view RMD 10-Q quarterly reports?
ResMed (RMD)'s most recent 10-Q quarterly report was filed on January 30, 2026. SignalX displays every RMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has RMD filed recently?
ResMed (RMD)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RMD insider trading activity (Form 4)?
SignalX aggregates every RMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RMD file with the SEC?
ResMed (RMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RMD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ResMed (RMD).
What is RMD's SEC CIK number?
ResMed (RMD)'s SEC CIK (Central Index Key) number is 943819. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 943819 to look up all RMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RMD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ResMed (RMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ResMed SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 35+ filings.